Explainer: Novo Nordisk’s two-brand bet, how Ozempic and Wegovy are carving India’s GLP-1 market

weight loss

Novo Nordisk has deployed a dual-brand strategy to crack India’s fast-growing GLP-1 segment, same molecule—semaglutide—under two distinct names - Ozempic and Wegovy. While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, reflecting the company’s effort to capture two massive but different patient pools, sometimes with significant overlap.

Different indications, different audiences Ozempic, launched in December 2025, is approved by India’s drug regulator for Type 2 diabetes management. Its primary indication is glycemic control and cardiovascular risk reduction, with weight loss considered a secondary benefit. Wegovy, introduced earlier in June, targets chronic weight management for adults with obesity (body mass index (BMI) of 30 and above or overweight people of BMI of 27 with comorbidities such as hypertension or sleep apnea. This distinction matters because India has more than 100 million diabetics and an estimated 250 million people living with obesity, creating two overlapping but distinct markets.

Dosing and device strategy The differentiation extends to dosing. Ozempic is capped at 1mg per week, while Wegovy is formulated for higher doses—up to 2.4 mg weekly—to deliver clinically significant weight reduction, often in the range of 15–20% of body weight. Both brands use Novo’s FlexTouch pen device, but the titration schedules and patient education differ, reducing the risk of off-label misuse.

Different price points

Pricing underscores the segmentation. Ozempic’s monthly cost starts at Rs.8,800 for the 0.25 mg starter dose and rises to Rs.11,175 for maintenance. Wegovy, positioned as a premium obesity solution, initially carried a steep price tag but saw a 37 percent price cut in November 2025. Today, Wegovy ranges from Rs.10,850 for starter doses to Rs.16,400 for higher strengths. The move was strategic: affordability remains the single biggest barrier to adoption in India, where GLP-1 uptake is concentrated among urban elites. A mid-November price cut for Wegovy triggered a 70 percent surge in consumption, proving strong price elasticity.

Why two brands? Novo Nordisk’s dual-brand play serves three purposes. First, market segmentation: diabetes and obesity are separate therapeutic categories with different reimbursement dynamics. Second, dosing clarity - higher obesity doses under Wegovy prevent confusion and off-label use of Ozempic. Third, regulatory and insurance compliance - diabetes drugs often qualify for coverage, while weight-loss treatments are typically out-of-pocket. Distinct branding simplifies filings and reimbursement negotiations.

The patent cliff Semaglutide’s patent expires in March 2026 in India, and generics are gearing up to enter the market. Analysts expect prices to fall by 50–70%, a shift that could democratize access and push GLP-1 adoption beyond Tier-1 cities. For Novo Nordisk, the challenge will be defending brand equity while navigating a price war that could reshape India’s obesity and diabetes care landscape.